Demonstrating the short-term and long-term value of gene and cellular therapies
This unique one-hour webinar — now available on demand — features some of the top gene and cell therapy leaders across Precision!
Larry Blandford, EVP, Managing Partner for Precision, moderates a panel discussion tackling the evergreen challenge of how to demonstrate the short and long-term value of a therapy when clinical data is lacking. The panelists represent a variety of stakeholder perspectives, from payers to IDNs to economists.
- Jeremy Schafer, Senior Vice President and Head of the Access Experience Team, leverages his payer experience at one of the top 5 largest PBMs.
- Avi Mamidi, former Formulary Manager and P&T Co-Chair at Sutter Health, speaks from the perspective of a leader at a large IDN about the impact on HCPs and patients.
- Rebecca Dean, Senior Research Scientist on the HEOR team, and David Carr, Senior Engagement Director on the Global Pricing and Market Access Team approach the topic from a research and economist perspective from US and UK, respectively.
